ReviewMicrobial biotechnology2025
Treatment of Clinically Important Bacteria With Cold Atmospheric Plasma.
Review in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Cold Atmospheric Plasma Against Methicillin-Resistant Staphylococcus aureus Biofilms: A Systematic Review of In Vitro Studies.BioMed research international · 2026Pooled it
- Possible Applications of Cold Atmospheric Plasma in Otorhinolaryngology: A Narrative Review.Antioxidants (Basel, Switzerland) · 2026Review
- Cold Atmospheric Plasma in Biomedicine and Pharmacology: Multidisciplinary Perspectives on Therapeutic Applications.ACS pharmacology & translational science · 2026Review
- Treatment of Clinically Important Bacteria With Cold Atmospheric Plasma.Microbial biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antimicrobial resistance (AMR), especially in clinically important bacteria, has posed serious challenges to clinical treatments. Novel and effective antimicrobial strategies are urgently needed to address AMR. Cold atmospheric plasma (CAP) is a new concept of disinfection method that kills bacteria through various active species and particles within an ionised and electrical-balanced gas. In this review, we introduced the generation of CAP and summarised its disinfection mechanisms. Moreover, we reviewed the applications of CAP in treating globally important bacteria, including Gram-positive bacteria such as Staphylococcus aureus, Enterococcus spp., Streptococcus pyogenes and Mycobacterium tuberculosis, as well as Gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii and Neisseria gonorrhoeae. Additionally, we discussed technological strategies to enhance CAP disinfection efficacy and evaluated the safety of CAP applications. We recommend CAP as an effective alternative technology for combating bacterial infections and hope that the comprehensive information provided in the present review will facilitate the development of CAP-based disinfection strategies to overcome AMR issues in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.